The transition of a breakthrough therapeutic compound from an exploratory research laboratory to a clinical-grade Good Manufacturing Practice (GMP) environment…
Read More

The transition of a breakthrough therapeutic compound from an exploratory research laboratory to a clinical-grade Good Manufacturing Practice (GMP) environment…
Read More
New York City–based Definium Therapeutics has reached a pivotal inflection point in the rapidly evolving landscape of psychedelic medicine. Following…
Read More
The landscape of psychiatric medicine is undergoing a profound transformation as pharmaceutical companies transition from chronic, daily-dosing regimens to high-intensity,…
Read More
New York City-based biotechnology firm Definium Therapeutics has reached a pivotal juncture in the development of its flagship psychedelic candidate,…
Read More
The pharmaceutical landscape for psychiatric care is currently witnessing a paradigm shift as New York City-based Definium Therapeutics advances its…
Read More